A meta-analysis has confirmed that intensive glycaemic control does not reduce the risk of mortality in Type 2 diabetes, and doesn’t seem to reduce the risk of microvascular or macrovascular disease. It does, however, increase the risk of severe hypoglycaemia by a third. What it doesn’t clarify is what the optimum level of control should be.
Treating children with seven days of high-dose intermittent ICSs at the first sign of respiratory illness controlled symptoms just as well as regular ICS treatment with a considerably lower ICS dose. However, since the relative doses used were 2 mg budesonide daily for the short-term treatment or 500 mg daily for regular, I’m not sure how helpful I’m going to find this.
And, reassuringly, it looks as though statins may be fairly safe long-term, in a huge RCT that has now been followed up eleven years after commencement (although this was five years of randomised treatment followed by six years in which most of the participants from the placebo arm ended up on statins, so I’m not sure how they analysed the data.)